A nasal spray that pairs a decongestant with a steroid produced noticeably better results than a steroid spray used by itself in adults with long-standing nasal blockage, according to a US clinical trial reported by الشرق الأوسط. Researchers at Washington University School of Medicine in St. Louis ran the study, and the findings were published Thursday in JAMA Otolaryngology–Head & Neck Surgery, the journal of the American Medical Association.
The trial enrolled 60 adults whose persistent congestion had not improved enough with standard steroid sprays. Participants were split into two groups: one used the combination spray, the other used budesonide alone, twice daily for four weeks, followed by a step-down in dosing over three weeks.
Why it matters
Chronic nasal blockage is a common and stubborn problem. It means air passes through the nasal passages with persistent or recurring difficulty, caused by swelling of the tissue lining the nose, excess mucus production, or physical obstruction inside the passages. It can be tied to allergies, chronic sinusitis or a deviated septum, and it can interfere with breathing, sleep, and the senses of smell and taste.
For patients who do not respond well to ordinary steroid sprays, options are limited. The new combination offers a possible alternative — one that, in this trial, did not trigger the rebound congestion that makes long-term decongestant use so problematic.
How the two drugs work together
The combination brings together oxymetazoline, a decongestant that narrows blood vessels in the nasal lining and opens the airways, and budesonide, a steroid that helps reduce inflammation and swelling.
The design targets two separate mechanisms behind a blocked nose at once. The decongestant acts quickly on the blood vessels, while the steroid works on the underlying inflammation. According to الشرق الأوسط, the researchers reported that the combined treatment delivered greater improvement among trial participants than the steroid alone.
The numbers behind the result
After four weeks, 83 percent of those using the combination spray recorded at least a moderate improvement, compared with 36 percent of those using the steroid by itself.
The gap appeared early. Two weeks into the trial, severity scores for nasal blockage had fallen by 69 percent in the combination group, against 41 percent in the steroid-only group.
Just as notable was what did not happen. None of the participants on the combination treatment showed signs of worsening congestion or rebound swelling during the first four weeks, even though they were using the full dose of the decongestant. Participants also tolerated the dose reduction during weeks five and six without a serious deterioration in symptoms.
After oxymetazoline was stopped entirely for one week, the trial recorded no cases of congestion flare-ups that required resuming the spray. Among participants whose symptoms had come under control, 75 percent held onto that improvement throughout the week without the decongestant.
The rebound problem the trial was watching for
The main hazard of overusing decongestant nasal sprays is a condition called rhinitis medicamentosa, also known as rebound congestion.
These sprays relieve symptoms quickly by constricting blood vessels, but using them longer than recommended can bring the swelling and blockage back. That can push people to use the spray again or increase their dose, which in turn makes it harder to stop.
Because the trial combined a decongestant with a steroid rather than relying on the decongestant alone, the researchers were able to test whether the steroid offset that cycle. In the four-week window, it appeared to.
What the trial does not show
The authors were careful about the limits of their evidence. According to الشرق الأوسط, they described the pairing as a promising option for chronic nasal blockage that does not respond to conventional treatment, but the results do not establish that rebound congestion can be prevented over the long term.
The study covered only 60 participants across seven weeks. Larger trials running for longer periods will be needed to judge both how well the treatment works and how safe it is over time.
For now, the findings point to a possible new route for patients who have run out of answers with steroid sprays alone — but one that still has to be confirmed at scale. Watch for follow-up studies with bigger groups and extended follow-up periods before any change in standard practice.
